Agenus logo

Agenus

291 employees · est. 1994 · Lexington, United States

VS
Merus N.V. logo

Merus N.V.

Oncology company developing Biclonics® bispecific antibody therapeutics. See our Community Guidelines: http://bit.ly/36c

253 employees · est. 2003 · Utrecht, The Netherlands

Agenus is the older company (1994 vs 2003).

Side-by-Side Comparison

Agenus Merus N.V.
Founded
1994 older 2003
Headquarters
Lexington, United States Utrecht, The Netherlands
Employees
291 253
Industry
Biotechnology, Health and Wellness, Medical Devices Biotechnology, Health Care, Health and Wellness
Funding Stage
Post Ipo Debt Post Ipo Equity
Total Funding
$346.14M $1.04B
Funding Rounds
8 11
Services
Not tracked yet Development of Cancer Treatments, Clinical Trials Management, Research and Development in Biotechnology, Multiclonics Therapeutics
Target Customers
Not tracked yet Cancer Patients, Healthcare Providers, Medical Researchers, Pharmaceutical Industry
Taxonomy
Immuno-oncology, Cancer Vaccines, Checkpoint Inhibitors, Immunotherapy, Cell Therapy, Antibodies, GMP Manufacturing Biclonics®, Bispecific Antibody Therapeutics, Antibody-based Biopharmaceuticals, Oligoclonics Technology, Immuno-oncology, Cancer Treatment, Antibody Engineering, Tumor Cell Inhibition, Immune System Activation, Biomarker Development, Clinical Trials, Oncology Research, Therapeutic Antibodies, Antibody Discovery, Cell Biology
Website
agenusbio.com merus.nl
Agenus logo

About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company, founded in 1994 and headquartered in Lexington, MA, aims to expand patient populations benefiting from cancer immunotherapy through combination app...

Merus N.V. logo

About Merus N.V.

Merus N.V., a biotechnology firm founded in 2003, is headquartered in The Netherlands. The company is at the forefront of developing innovative oncology solutions using its proprietary Biclonics® bispecific antibody therapeutics. This pioneering approach enables simultaneous multi-targeted tumor att...

We will tell you when either one moves

BounceWatch watches Agenus and Merus N.V. for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Agenus and Merus N.V. — by email.

Frequently Asked Questions

Agenus. Merus N.V. — Oncology company developing Biclonics® bispecific antibody therapeutics. See our Community Guidelines: http://bit.ly/36c. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Agenus has raised $346.14M while Merus N.V. has raised $1.04B.
Agenus and Merus N.V. operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Agenus with someone else

Start typing a company name or domain.

Related Comparisons

Compiled from the BounceWatch company index. We last looked at Agenus on 12 Sep 2024, and Merus N.V. on 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy